GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Nasus Pharma Ltd
Nasus Pharma's value, like that of any early-stage pharmaceutical company, is determined by the potential of its developments. Its nasal drug delivery technology could be revolutionary, and its potential share price will reflect the success of its clinical trials.
Share prices of companies in the market segment - Narco farm
Nasus Pharma is an Israeli biopharmaceutical company developing intranasal powder sprays for emergency drug delivery, such as naloxone for opioid overdose. We've classified it in the "Narco Pharma" segment. The chart below shows the overall dynamics in the sector, which is seeking fast and effective ways to deliver critically important medications.
Broad Market Index - GURU.Markets
Nasus Pharma is a pharmaceutical company developing nasal spray powders for emergency medical treatment, such as opioid overdose. Its unique technology makes it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Nasus compares to it.
Change in the price of a company, segment, and market as a whole per day
NSRX - Daily change in the company's share price Nasus Pharma Ltd
The daily price change of Nasus Pharma Ltd reflects the high volatility inherent in companies developing intranasal sprays for emergency medicine. This indicator is a measure of sensitivity to news about clinical trials and partnerships.
Daily change in the price of a set of shares in a market segment - Narco farm
The daily price change of Nasus Pharma Ltd reflects the high volatility inherent in companies developing intranasal sprays for emergency medicine. This indicator is a measure of sensitivity to news about clinical trials and partnerships.
Daily change in the price of a broad market stock, index - GURU.Markets
Nasus Pharma develops powder nasal sprays for drug delivery, including for emergency use. This is an innovative approach in pharmaceuticals. The company's shares respond to news of clinical trials and partnerships, and these events create a unique rhythm that becomes part of the overall market pulse, reflected on the chart.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Nasus Pharma Ltd
Nasus Pharma Ltd's annual performance is a story of innovative nasal spray development. Its 12-month market capitalization depends entirely on progress in clinical trials of its drugs, including a nasal spray for emergency opioid overdose treatment. Success could lead to a faster and more convenient drug delivery method.
Annual dynamics of market capitalization of the market segment - Narco farm
Nasus, a privately held pharmaceutical company, likely specializes in developing nasal sprays for drug delivery. Its growth depends on success in clinical trials. Its valuation will reflect investor confidence in its unique technology platform, which potentially outperforms the overall pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Nasus Pharma is privately held and not publicly traded. Its market performance cannot be analyzed. As a developer of intranasal medications, its business is at the forefront of medical technology. Its success is determined by clinical data and its ability to bring its product to market.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Nasus Pharma Ltd
Nasus Pharma develops powder nasal sprays. Its monthly performance depends on progress in the development and commercialization of its products, such as its emergency naloxone spray. News of partnerships and regulatory approvals are key drivers.
Monthly dynamics of market capitalization of the market segment - Narco farm
Nasus Pharma is developing a nasal powder spray for emergency opioid overdose relief. This product serves a critical and socially significant niche. Its success depends on regulatory approval and government contracts. The pharmaceutical industry chart provides only a general overview for evaluating this highly specialized, yet potentially life-saving product.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Nasus Pharma develops powdered nasal sprays. It is a highly specialized pharmaceutical company. Its shares move not with the market, but on news about the development and approval of its products. The chart will reflect investors' confidence in the potential of its unique drug delivery technology, not general economic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Nasus Pharma Ltd
Nasus Pharma, a company developing intranasal drug delivery sprays, whose weekly stock performance reflects innovation in the pharmaceutical industry. News about clinical trials, partnerships, and regulatory approvals drive highly volatile short-term trends.
Weekly dynamics of market capitalization of the market segment - Narco farm
Nasus Pharma is developing powder nasal sprays for emergency drug delivery. This unique delivery method could be critical in certain situations. The chart below shows how the market views this technology compared to overall trends in the pharmaceutical sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Nasus Pharma develops nasal sprays. As a development-stage biotech, its shares are highly volatile. The chart shows that their movements are driven by technology news rather than general market trends.
Market capitalization of the company, segment and market as a whole
NSRX - Market capitalization of the company Nasus Pharma Ltd
The Nasus Pharma chart is a financial barometer reflecting the company's performance in the pharmaceutical sector. It shows how the market views its pipeline, its scientific platform, and its commercialization potential. Its dynamics provide an indicator of news about clinical trials and strategic partnerships.
NSRX - Share of the company's market capitalization Nasus Pharma Ltd within the market segment - Narco farm
Nasus Pharma's market share in the pharmaceutical sector reflects its innovative approach to nasal drug delivery. Its market share is based on the potential of its platform for creating powder nasal sprays, which can provide rapid drug delivery, for example, in emergency situations.
Market capitalization of the market segment - Narco farm
Nasus Pharma is a company developing new drug formulations. The chart below shows the overall market capitalization of the entire pharmaceutical industry. Its dynamics provide a backdrop against which the company strives to improve existing drugs, making them more convenient and effective.
Market capitalization of all companies included in a broad market index - GURU.Markets
Nasus Pharma is an Israeli company developing nasal powder sprays for emergency drug delivery, such as in the treatment of opioid overdoses. Its market capitalization is a bet on this technology. The chart below shows the economic impact of emergency medicine innovations.
Book value capitalization of the company, segment and market as a whole
NSRX - Book value capitalization of the company Nasus Pharma Ltd
Nasus Pharma is a clinical-stage biopharmaceutical company. Its book value is primarily derived from investor cash. The chart below shows how this capital is being spent on the development of its nasal spray. This is its financial "headroom."
NSRX - Share of the company's book capitalization Nasus Pharma Ltd within the market segment - Narco farm
Nasus Pharma is a company developing nasal spray powders. Its value lies in its unique delivery technology. Its share of tangible assets will be minimal, which is typical for an R&D company whose capital is intellectual property.
Market segment balance sheet capitalization - Narco farm
Nasus Pharma is a pharmaceutical company. Its value is created in the laboratories where its unique technology for nasal powder delivery is developed. This is a "light" model. The graph below illustrates the extent to which the pharmaceutical industry as a whole relies on tangible assets.
Book value of all companies included in the broad market index - GURU.Markets
Nasus Pharma's balance sheet represents capital invested in the development of an intranasal powder for emergency opioid overdose relief. The company's assets represent the hope of creating a more convenient and effective means of saving lives amid the opioid crisis.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Nasus Pharma Ltd
Nasus Pharma (likely a reference to Altimmune, ALT) develops intranasal vaccines and therapeutics. Its value lies in its nasal drug delivery platform. The chart shows how the market values its pipeline, particularly in hot areas like obesity, and its innovative drug delivery method.
Market to book capitalization ratio in a market segment - Narco farm
Nasus Pharma (likely a reference to TFF Pharmaceuticals) is developing a technology for converting injectable drugs into dry powder for inhalation. Its value lies in this platform. The chart shows the premium the market is paying for the potential of this breakthrough technology.
Market to book capitalization ratio for the market as a whole
Nasus Pharma is likely developing drugs for intranasal delivery. The chart for such companies shows how the market values this innovative drug delivery method. Their market capitalization is a bet on their technology ensuring rapid and effective drug delivery through the nasal mucosa, which could be critical in emergency situations.
Debts of the company, segment and market as a whole
NSRX - Company debts Nasus Pharma Ltd
Nasus Pharma, which develops intranasal drugs, is working to improve drug delivery methods. For a pharmaceutical company in the development stage, debt instruments can be a way to finance clinical trials and prepare for the product's launch.
Market segment debts - Narco farm
Nasus Pharma is a company developing nasal powder sprays that can provide rapid drug delivery, for example, in cases of anaphylactic shock. The chart shows common financial indicators for the pharmaceutical sector, which can be used to assess how this small company is funding the development and clinical trials of its innovative drug delivery platform.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Nasus Pharma Ltd
Nasus Pharma develops nasal sprays for emergency drug delivery, for example, in cases of anaphylactic shock. The development and certification of such products is a lengthy process. This chart shows the role debt plays in funding R&D and clinical trials. This helps assess the company's financial strength before entering the market.
Market segment debt to market segment book capitalization - Narco farm
The development of intranasal sprays for emergency medical use, like Nasus Pharma's, is a niche industry within the pharmaceutical industry. This chart shows how the sector as a whole funds its R&D. It allows us to assess how the financial model of a company focused on non-invasive drug delivery differs from that of traditional injectables.
Debt to book value of all companies in the market
Nasus Pharma develops powder nasal sprays for emergency medicine. Pharmaceutical innovation, even in such narrow niches, requires capital. The chart provides context for assessing their debt strategy compared to pharmaceutical giants and the overall debt level in the market.
P/E of the company, segment and market as a whole
P/E - Nasus Pharma Ltd
This figure for Nasus Pharma, an Israeli company developing powdered nasal sprays, reflects investor expectations. For a company in the development stage, its value is determined not by current profits, but by the potential of its technology for rapid drug delivery, for example, in emergency situations.
P/E of the market segment - Narco farm
This indicator represents the average valuation for the biotech sector in which Nasus Pharma operates. It reflects the overall level of hope and expectation in the development of new drug delivery systems. The chart serves as a barometer of investor confidence in the future of nasal sprays.
P/E of the market as a whole
Nasus Pharma develops nasal powder sprays for emergency drug delivery, such as naloxone to reverse opioid overdoses. This technology allows for rapid administration of medications. This chart shows market sentiment in the pharmaceutical sector. It helps understand how the market views the potential of this innovative delivery system and its application in critical medical situations.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Nasus Pharma Ltd
Nasus Pharma develops nasal powder sprays for emergency drug delivery, specifically naloxone for opioid overdose reversal. The company's future depends on regulatory approval and demand for its innovative delivery system. This chart shows investor expectations for its ability to offer a more effective and easier-to-use solution for emergency situations.
%20P%2FE%20Nasus%20Pharma%20Ltd&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Nasus-Pharma-Ltd&v=1772668584427 "Chart of the company's future (projected) P/E Nasus Pharma Ltd")
Future (projected) P/E of the market segment - Narco farm
Nasus Pharma is an Israeli biopharmaceutical company developing powder nasal sprays for emergency medicine. This technology enables rapid drug delivery to the brain. The chart reflects expectations for the biotech sector, providing context for evaluating this innovative, yet still-in-development, technology.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Narco-farm&v=1772668584434 "Future (projected) P/E graph of the market segment - Narco farm")
Future (projected) P/E of the market as a whole
Nasus Pharma is an Israeli biopharmaceutical company developing nasal sprays for emergency drug delivery. Their flagship product is a naloxone nasal spray for opioid overdose treatment. This general expectations chart shows investor sentiment toward pharmaceutical innovations that address pressing social issues, which can facilitate funding.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772668584438 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Nasus Pharma Ltd
Nasus Pharma develops nasal powder sprays for emergency drug delivery. This chart shows the company's financial position as it moves toward commercialization. Future profits depend on approval for its products, such as an epinephrine nasal spray for the treatment of anaphylactic shock.
Profit of companies in the market segment - Narco farm
Nvni Group Limited is a Brazilian company providing cloud-based software solutions for businesses. Its profitability depends on the pace of digitalization in Latin America. This chart illustrates how economic growth and technology penetration in developing countries are creating favorable conditions for SaaS providers, but competition and economic instability remain risks.
Overall market profit
Nasus Pharma is developing a nasal powder spray for emergency opioid overdose relief. The company aims to offer a more effective and faster-acting alternative to existing medications. Its success depends on the results of clinical trials and regulatory approval for this critically important product.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Nasus Pharma Ltd
Nasus Pharma is an Israeli company developing nasal powder sprays for emergency medical treatment, specifically for the treatment of opioid overdose. Its revenue forecast is dependent on regulatory approval and government procurement. This chart reflects analyst expectations regarding the fight against the opioid crisis and the potential of its product.
%20profit%20of%20the%20company%20Nasus%20Pharma%20Ltd&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Nasus-Pharma-Ltd&v=1772668584530 "Graph of future (projected) profit of the company Nasus Pharma Ltd")
Future (predicted) profit of companies in the market segment - Narco farm
Nasus Pharma is likely a pharmaceutical company developing drugs delivered intranasally. This route of administration can provide rapid drug action, for example, for migraines or allergies. This chart shows profitability forecasts for the pharmaceutical sector. It reflects the potential of new, more patient-friendly drug delivery systems.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Narco-farm&v=1772668584534 "Graph of future (predicted) profits of companies in a market segment - Narco farm")
Future (predicted) profit of the market as a whole
Nasus Pharma is developing nasal powder sprays for emergency drug delivery. The company's success depends on clinical trials and regulatory approval. The overall economic outlook, as shown in this chart, influences the availability of capital for research and strategic decisions in the pharmaceutical industry.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772668584544 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Nasus Pharma Ltd
Nasus Pharma is an Israeli biopharmaceutical company developing intranasal powder formulations. Its technology enables drug delivery directly to the brain or systemic bloodstream via the nose. The chart reflects investor valuation of its innovative delivery platform, which has the potential to improve the treatment of many conditions.
P/S market segment - Narco farm
Nasus Pharma Ltd is a clinical-stage biopharmaceutical company developing intranasal powdered medications for emergency medical treatment, such as a nasal spray for the treatment of severe allergic reactions. This chart shows the average valuation in the sector, allowing one to assess the market's perception of the revenue potential of Nasus Pharma's developments.
P/S of the market as a whole
Nasus Pharma develops powder nasal sprays that can provide rapid drug delivery, including for emergency situations such as opioid overdose. This chart, showing average valuations, clearly highlights the gap between traditional businesses and companies developing innovative drug delivery systems.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Nasus Pharma Ltd
Nasus Pharma is a company developing intranasal powder formulations that enable rapid drug delivery in emergency situations. This chart reflects investor expectations for the future success of its platform. The valuation is based on potential revenue from its naloxone nasal spray for opioid overdose treatment and other products.
%20P%2FS%20Nasus%20Pharma%20Ltd&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Nasus-Pharma-Ltd&v=1772668584614 "The graph of the company's future (projected) P/S Nasus Pharma Ltd")
Future (projected) P/S of the market segment - Narco farm
Nasus Pharma develops powder nasal sprays for emergency drug delivery. Its leading product is designed to treat severe allergic reactions (anaphylaxis). The chart shows how the market estimates Nasus Pharma's future sales, reflecting the potential of its innovative and convenient drug delivery system.
%20P%2FS%20market%20segment%20graph%20-%20Narco%20farm&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Narco-farm&v=1772668584630 "Future (projected) P/S market segment graph - Narco farm")
Future (projected) P/S of the market as a whole
This graph reflects the search for new solutions for emergency medical care. Nasus Pharma is developing nasal powders for emergency situations, such as the treatment of anaphylactic shock. Their innovative delivery method could make first aid faster and more accessible, supporting the belief that technology can save lives.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772668584632 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Nasus Pharma Ltd
Nasus Pharma is an Israeli clinical-stage biopharmaceutical company developing intranasal powder formulations. At this stage, the company likely has no significant commercial revenue. Its cash flow reflects the R&D phase, which is funded by investments rather than ongoing sales.
Sales of companies in the market segment - Narco farm
Nasus Pharma is a company developing nasal spray powders for emergency drug delivery, specifically naloxone for opioid overdose reversal. This chart shows the overall revenue in the cannabis sector, illustrating the urgent need for fast and easy-to-use lifesaving treatments in critical situations.
Overall market sales
Nasus Pharma develops powder nasal sprays for emergency drug delivery. Its flagship product is a naloxone nasal spray for opioid overdose treatment. The company's success depends on regulatory approval and demand from emergency services. This overall economic consideration is less important than the social and medical need for its products.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Nasus Pharma Ltd
Nasus Pharma is an early-stage company developing nasal powder sprays for emergency drug delivery, such as for the treatment of anaphylactic shock. Its future depends on the success of clinical trials. The revenue projections are highly speculative and reflect only the most distant expectations of analysts regarding future commercialization.
%20sales%20of%20the%20company%20Nasus%20Pharma%20Ltd&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Nasus-Pharma-Ltd&v=1772668584661 "Schedule of future (projected) sales of the company Nasus Pharma Ltd")
Future (projected) sales of companies in the market segment - Narco farm
Nasus Pharma develops nasal powder sprays for emergency drug delivery. Its flagship product is designed to treat severe allergic reactions, and intranasal naloxone is also being developed. This chart shows projected revenue for the entire pharmaceutical sector, reflecting analysts' expectations for growth in the emergency medication market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Narco-farm&v=1772668584669 "Schedule of future (projected) sales of companies in the market segment - Narco farm")
Future (projected) sales of the market as a whole
Nasus Pharma develops nasal powder sprays for emergency drug delivery, such as naloxone for opioid overdose. The company's success depends on securing contracts from government and healthcare institutions. This general economic activity impacts government budgets for healthcare and crisis response.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772668584678 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Nasus Pharma Ltd
Nasus Pharma develops dry powder nasal sprays for emergency drug delivery. This metric reflects the company's financial progress. It demonstrates the investment required to conduct clinical trials and obtain regulatory approvals, which are key steps toward commercializing its innovative platform.
Market segment marginality - Narco farm
Nasus Pharma is developing powder nasal sprays for emergency drug delivery. Profitability will depend on the commercialization of this innovative platform. This metric reflects the company's operational structure during the R&D phase compared to other pharmaceutical companies in this niche.
Market marginality as a whole
Nasus Pharma (formerly Bio-Nexus) develops powdered nasal sprays for emergency drug delivery. Their flagship product is a nasal spray containing naloxone for opioid overdose treatment. Their success depends on regulatory approval and government procurement. This overall profitability curve is less important to them than government health policy.
Employees in the company, segment and market as a whole
Number of employees in the company Nasus Pharma Ltd
Nasus Pharma develops nasal powder sprays for emergency drug delivery. While in the development stage, the company has a small team. This chart shows the dynamics of the team of scientists and product development specialists working on the development and clinical testing of their innovative delivery systems.
Share of the company's employees Nasus Pharma Ltd within the market segment - Narco farm
Nasus Pharma develops intranasal powder sprays. This chart shows the concentration of unique pharmacologists and chemists. The proportion of these specialists reflects its innovative approach to creating drugs that act quickly and are absorbed through the nasal mucosa, for example, for migraine relief.
Number of employees in the market segment - Narco farm
Nasus Pharma Ltd. is an Israeli biopharmaceutical company developing intranasal powder sprays for emergency drug delivery. This chart shows overall employment in the pharmaceutical sector. It illustrates the company's innovative approach to creating products that can quickly deliver active ingredients to the body in critical situations.
Number of employees in the market as a whole
Nasus Pharma develops nasal powder sprays for emergency drug delivery, such as in cases of opioid overdose or anaphylactic shock. Rapid action can save lives. This employment chart also reflects the pharmaceutical sector, where such innovative companies, although small, are solving critical medical problems, requiring the employment of scientists and chemists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Nasus Pharma Ltd (NSRX)
Nasus Pharma Ltd. likely develops pharmaceuticals for nasal administration. This chart should indicate a high market capitalization per employee, which is typical for biotech. The market evaluates the potential of a unique drug delivery system and development pipeline, not the day-to-day operations of a small team.
%20of%20the%20company%20Nasus%20Pharma%20Ltd%20(NSRX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Nasus-Pharma-Ltd-NSRX&v=1772668584728 "Chart of market capitalization per employee (in thousands of dollars) of the company Nasus Pharma Ltd (NSRX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Narco farm
Nasus Pharma, as its name suggests, develops nasal drug delivery systems. This could be an innovative platform for rapid drug delivery. This metric reflects how investors view the potential of this technology. The high market capitalization per employee reflects a bet that their delivery method will prove effective and in demand for a variety of medications.
%20by%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Narco-farm&v=1772668584741 "Market capitalization per employee (in thousands of dollars) by market segment - Narco farm")
Market capitalization per employee (in thousands of dollars) for the overall market
Nasus Pharma Ltd. is likely a pharmaceutical company specializing in nasal medications. This delivery method can improve the efficacy and ease of administration of certain medications. The employee's evaluation will reflect the potential of this technology platform and specific products in its portfolio.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772668584760 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Nasus Pharma Ltd (NSRX)
Nasus Pharma (NSRX) is a private Israeli biotech R&D company. They are developing a nasal spray powder (FEND), which they claim can block viruses. This chart reflects their R&D status: it shows the net loss (investment in research) per scientist.
%20Chart%20Nasus%20Pharma%20Ltd%20(NSRX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Nasus-Pharma-Ltd-NSRX&v=1772668584777 "Company Profit Per Employee (in thousands of dollars) Chart Nasus Pharma Ltd (NSRX)")
Profit per employee (in thousands of dollars) in the market segment - Narco farm
Nasus Pharma develops powdered medications for nasal administration. For a company in the R&D stage, this metric is irrelevant. The graph shows the industry norm. If their delivery technology is successful, NSRX will be able to license it, generating high profits with minimal staffing, far exceeding the industry benchmark.
%20in%20the%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Narco-farm&v=1772668584779 "Chart of profit per employee (in thousands of dollars) in the market segment - Narco farm")
Profit per employee (in thousands of dollars) for the market as a whole
Nasus Pharma (NSRX) is an Israeli company developing medications (primarily powdered) for intranasal administration, such as for emergency treatment of opioid overdose. This is R&D. This chart shows the company is in the development stage. Earnings per employee are negative until the products are approved.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772668584784 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Nasus Pharma Ltd (NSRX)
For Nasus Pharma, a company developing nasal spray powders for emergency medicine, this graph reflects the commercialization stage. Future revenue growth per employee will depend on the approval and adoption of its innovative products for rapid drug delivery.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Nasus-Pharma-Ltd-NSRX&v=1772668584794 "Sales chart per company employee Nasus Pharma Ltd (NSRX)")
Sales per employee in the market segment - Narco farm
Nasus Pharma is an Israeli biopharmaceutical company developing drugs for intranasal delivery (in spray form), for example, for emergency treatment. This is R&D. This metric reflects the average revenue per employee in the segment. It helps assess how productive their R&D team is in advancing their drug delivery technology.
Sales per employee for the market as a whole
Nasus Pharma (NSRX) is an Israeli biopharmaceutical company developing drugs for intranasal (through the nose) delivery. It is an R&D company. This indicator for NSRX is an indicator of the future. Zero values currently reflect the R&D stage. An upward trend in the graph would indicate that their technology (for example, a nasal spray for migraines) has received approval and is entering the market.
Short shares by company, segment and market as a whole
Shares shorted by company Nasus Pharma Ltd (NSRX)
Nasus Pharma is apparently an Israeli company developing nasal sprays for emergency drug delivery. This chart likely reflects investor bets that its technology will not be approved by regulators or that the company will be unable to find a commercial partner to bring its products to market.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Nasus-Pharma-Ltd-NSRX&v=1772668584816 "Short Shares Chart for the Company Nasus Pharma Ltd (NSRX)")
Shares shorted by market segment - Narco farm
Nasus Pharma (NSRX) is a company developing pharmaceuticals in the form of nasal sprays. This chart shows the overall short position in the speculative pharmaceutical development sector. It reflects investor doubts about the viability of the nasal delivery method for specific drugs or the success of their clinical trials.
Shares shorted by the overall market
Nasus Pharma develops emergency drug delivery systems, such as nasal delivery. This business is relatively unaffected by economic cycles. However, this chart reflects general market pessimism. When investors are fearful, they can sell everything, including stable sectors, in pursuit of cash.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Nasus Pharma Ltd (NSRX)
This chart for Nasus Pharma reflects the volatility inherent in a biotech focused on drug delivery via nasal sprays. The market is extremely sensitive to news. Successful data on the efficacy of their intranasal drugs or partnerships can trigger a surge in demand, driving the oscillator above 70. Any regulatory obstacles or delays, on the other hand, lead to sharp sell-offs.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Nasus-Pharma-Ltd-NSRX&v=1772668584848 "RSI 14 indicator chart for the company's stock Nasus Pharma Ltd (NSRX)")
RSI 14 Market Segment - Narco farm
Nasus Pharma (NSRX) is a "spray" instead of an injection (Israel). They are developing *intranasal* (into the nose) *delivery* of powdered medications (for example, *naloxone* for overdose). The "Narco farm" sector (biotech/delivery) is living on "hype." RSI_14_Seg shows the "temperature" of the *entire* industry. It helps to understand: is NSRX's growth their "niche" or the *general* "hype"?
RSI 14 for the overall market
Nasus Pharma (NSRX) is a biotech R&D company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast NSRX (Nasus Pharma Ltd)
Nasus Pharma is an Israeli company that has developed a technology for delivering powdered medications via nasal spray (e.g., for emergency use). This chart shows the speculative average price target from analysts, reflecting their assessment of the commercial potential of this unique R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-NSRX-Nasus-Pharma-Ltd&v=1772668584970 "A chart showing analyst consensus forecasts for the expected stock price. NSRX (Nasus Pharma Ltd)")
The difference between the consensus estimate and the actual stock price NSRX (Nasus Pharma Ltd)
Nasus Pharma (NSRX) is an Israeli biotech company developing nasal drug delivery technology (nasal spray) for emergency situations (e.g., opioid overdose). This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the potential analysts see in their delivery platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-NSRX-Nasus-Pharma-Ltd&v=1772668585102 "A chart showing the difference between the consensus forecast and the actual stock price. NSRX (Nasus Pharma Ltd)")
Analyst consensus forecast for stock prices by market segment - Narco farm
Nasus Pharma is an Israeli biotech company developing a nasal spray (FENSOLVI) for the delivery of drugs (such as opioids) for rapid anesthesia. This chart shows general expectations for the pharmaceutical sector. It reflects whether experts believe in the potential of nasal delivery for specific medical needs.
Analysts' consensus forecast for the overall market share price
Nasus Pharma is an Israeli company developing a nasal spray (powder) for emergency drug delivery, specifically naloxone (an opioid overdose treatment). This chart shows the overall risk appetite. For Nasus, a company with an innovative delivery platform, overall market optimism is important for funding, but their success depends more on FDA approval.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Nasus Pharma Ltd
Nasus Pharma is an Israeli biotech company developing nasal sprays for emergency situations. Their key product is nasal naloxone (for opioid overdose) and other fast-acting medications. This graph summarizes their R&D progress and reflects their clinical progress and their ability to compete with existing delivery methods.
AKIMA Market Segment Index - Narco farm
Nasus Pharma (NSRX) is an Israeli biopharmaceutical company developing emergency medicine products, including a nasal spray containing naloxone (an opioid overdose treatment) and other products. The chart shows the average index for the segment, helping investors assess how Nasus Pharma competes in its niche compared to the pharmaceutical industry average.
The AKIM Index for the overall market
Nasus Pharma is a biopharmaceutical company developing intranasal powder products for viral protection and the treatment of emergency conditions. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this niche product stacks up against overall economic trends.
